- March 12, 2014 - N30 Announces Start of Oral Dosing of N91115 in a Phase 1 Clinical Trial
- October 15, 2013 - N30 Announces Presentations at the 2013 North American Cystic Fibrosis Conference
- April 2, 2013 - N30 Announces Presentation of Preclinical Data at the Basic Science Meeting of the European Cystic Fibrosis Society
- March 13, 2013 - N30 Announces First Patient Treated in Clinical Trial of N6022 in Cystic Fibrosis
- October 8, 2012 - N30 Names Sherif Gabriel, Ph.D. as VP Research
- October 9, 2014 - Safety, Tolerability, and Pharmacokinetics of the Oral S-Nitrosoglutathione Reductase Inhibitor N91115: A Multiple Ascending-Dose Study In Healthy Subjects
- October 9, 2014 - Safety, Tolerability, and Pharmacokinetics of the Intravenous S-NitrosoglutathioneReductaseInhibitor N6022: An Ascending-Dose Study in Subjects Homozygous for the F508del-CFTRMutation
- October 4, 2014 - Pharmacological Correction and Acute Inhibition of GSNOR Results in Improved In Vitro CFTR Function
- October 4, 2014 - Neutrophil Elastase-Mediated CFTR Damage is Rescued by Intracellular Bioavailable GSNO
- March 21, 2014 - Primary airway epithelial cells expanded with feeder cells and ROCK inhibitor for screening novel GSNOR inhibitors and CFTR correctors
More posters |
October 9, 2014 Safety, Tolerability, and Pharmacokinetics of the Intravenous S-NitrosoglutathioneReductaseInhibitor N6022: An Ascending-Dose Study in Subjects Homozygous for the F508del-CFTRMutation
Scott Donaldson,Jennifer Taylor-Cousar,Daniel Rosenbluth,Pamela Zeitlin, James Chmiel, Manu Jain, Karen McCoy, Edith Zemanick
Background:Preservation of S-nitrosoglutathione(GSNO), through inhibition of its primary catabolizing enzyme S-nitrosoglutathionereductase(GSNOR), may provide a novel therapeutic strategy in cystic fibrosis (CF). In experimental models, small molecule inhibitors of GSNOR have been shown to improve the function of F508del-CFTRand inhibit inflammatory mediators that correlate with lung function decline in CF. More…(400Kb)
Comments are closed.
|
- January 24, 2013 - Pharmacological Inhibition of S-Nitrosoglutathione Reductase Improves Endothelial Vasodilatory Function in Rats in vivo
- December 28, 2012 - ADH IB Expression, but Not ADH III, Is Decreased in Human Lung Cancer
- February 15, 2012 - Mechanism of Inhibition for N6022, a First-in-Class Drug Targeting GSNOR
- January 13, 2012 - Structure–activity relationship of pyrrole based GSNOR inhibitors
- August 25, 2011 - Preclinical 28-Day Inhalation Toxicity Assessment of S-Nitrosoglutathione
- July 26, 2011 - Discovery of potent and novel GSNOR inhibitors devoid of cytochrome P450 activities
- April 19, 2011 - Structure–activity relationships of pyrrole based GSNOR inhibitors: Pyrrole regioisomers and propionic acid replacement
|
